Alto Neuroscience Inc (ANRO) Stock Price, Quote & News

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 200 0412

Website: www.altoneuroscience.com

Address:

650 Castro Street, Suite 450, Mountain View, United States

TripleWitch Jul. 14 at 1:44 AM

$ANRO $PSNL You must mean the one that did the after hours equity offering, no? 🤷‍♂️

0 · Reply

RunnerSignals Jul. 13 at 7:53 PM

red to green $PSNL and $ANRO flipped the script into the close, but one reversal had the cleaner volume signature. traders may be watching the wrong winner

0 · Reply

focafoca99 Jul. 13 at 12:12 PM

$ANRO estimated its cash, cash equivalents and restricted cash at about $244.2 million as of June 30, 2026.

0 · Reply

MomentumSqueeze Jul. 13 at 11:44 AM

$ANRO news

0 · Reply

DiamondHandsJimbo Jul. 10 at 5:59 PM

$ANRO 😝🔥🚀

0 · Reply

DiamondHandsJimbo Jul. 10 at 4:43 PM

$ANRO show me some green LMAO… Entry at $26.14 🤞🚀

0 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:57 PM

$RILY $SLS $ANRO $OUST $POET The other half of that message from one year ago. What do you guys have planned for the next year? I guess, more importantly... What do WE have planned for next year?

3 · Reply

Ccperk Jun. 26 at 7:48 PM

$ANRO not exactly sure what’s going on here. Partnership or buyout imminent? Who knows

0 · Reply

focafoca99 Jun. 15 at 12:32 PM

$ANRO showed significant anhedonia reduction in a Nature Medicine study of pramipexole.

0 · Reply

dumb_money_wins_again Jun. 10 at 2:30 PM

$ANRO bring this back down to 3 dollars lol

0 · Reply

Alto Neuroscience prices 3.78M shares at $26.48 in registered direct offering

Jul 13, 2026, 7:47 AM EDT - 7 days ago

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Jun 16, 2026, 7:00 AM EDT - 5 weeks ago

Alto Neuroscience Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference

2026-06-15T12:16:21.000Z - 5 weeks ago

Alto Neuroscience highlights publication in Nature Medicine on Prime-Praxol

Jun 15, 2026, 8:03 AM EDT - 5 weeks ago

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Jun 15, 2026, 7:00 AM EDT - 5 weeks ago

Alto Neuroscience Slides: Corporate presentation

Jun 3, 2026, 9:20 AM EDT - 6 weeks ago

Alto Neuroscience Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T12:48:57.000Z - 7 weeks ago

Alto Neuroscience appoints Miller to Board of Directors

May 28, 2026, 8:03 AM EDT - 7 weeks ago

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

2026-05-22T11:55:51.000Z - 2 months ago

Alto Neuroscience price target lowered to $33 from $35 at BofA

2026-05-18T11:43:06.000Z - 2 months ago

Alto Neuroscience price target lowered to $36 from $38 at Baird

May 15, 2026, 8:27 AM EDT - 2 months ago

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

2026-05-14T17:24:06.000Z - 2 months ago

Alto Neuroscience price target raised to $24 from $21 at Wedbush

May 13, 2026, 8:15 PM EDT - 2 months ago

Alto Neuroscience Transcript: Bank of America Global Healthcare Conference 2026

2026-05-13T13:07:17.000Z - 2 months ago

Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year

May 13, 2026, 7:03 AM EDT - 2 months ago

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 7:00 AM EDT - 2 months ago

Alto Neuroscience Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

Alto Neuroscience Quarterly report: Q1 2026

May 11, 2026, 6:00 PM EDT - 2 months ago

Alto Neuroscience Slides: Corporate presentation

May 11, 2026, 4:05 PM EDT - 2 months ago

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

2026-05-04T20:26:52.000Z - 2 months ago

Alto Neuroscience initiated with a Buy at BofA

2026-05-04T12:31:04.000Z - 2 months ago

Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

May 4, 2026, 8:03 AM EDT - 2 months ago

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

2026-04-29T17:18:32.000Z - 2 months ago

Alto Neuroscience participates in a conference call with H. C. Wainwright

2026-04-21T13:15:23.000Z - 3 months ago

Alto Neuroscience initiates Phase 2b trial of ALTO-207 in TRD

Apr 21, 2026, 8:03 AM EDT - 3 months ago

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

2026-04-10T20:05:23.000Z - 3 months ago

Alto Neuroscience files to sell 6M shares of common stock for holders

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Alto Neuroscience Registration statement: Registration filing

2026-04-02T16:29:46.000Z - 3 months ago

Alto Neuroscience’s ALTO-101 miss doesn’t impact thesis, says H.C. Wainwright

2026-04-02T13:05:12.000Z - 3 months ago

Alto Neuroscience price target lowered to $21 from $22 at Wedbush

2026-04-02T12:36:19.000Z - 3 months ago

Alto Neuroscience price target lowered to $38 from $41 at Baird

2026-04-02T12:34:41.000Z - 3 months ago

Alto Neuroscience price target lowered to $44 from $49 at JonesResearch

2026-04-01T20:36:14.000Z - 3 months ago

Alto Neuroscience announces ALTO-101 did not achieve statistical significance

Apr 1, 2026, 4:30 PM EDT - 3 months ago

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Alto Neuroscience Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 4 months ago

Alto Neuroscience Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 4 months ago

Alto Neuroscience Proxy statement: Proxy filing

2026-03-18T11:15:42.000Z - 4 months ago

Alto Neuroscience price target raised to $41 from $22 at Baird

Mar 17, 2026, 12:00 PM EDT - 4 months ago

Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum

Mar 16, 2026, 7:03 AM EDT - 4 months ago

Alto Neuroscience Announces $120 Million Private Placement Financing

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Alto Neuroscience Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Alto Neuroscience Annual report: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 4 months ago

Alto Neuroscience Slides: Corporate presentation

Mar 16, 2026, 6:03 AM EDT - 4 months ago

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 13, 2026, 8:03 AM EDT - 4 months ago

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Mar 3, 2026, 1:50 PM EST - 4 months ago

Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 8:04 AM EST - 5 months ago

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Feb 3, 2026, 8:27 AM EST - 5 months ago

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Jan 14, 2026, 7:27 AM EST - 6 months ago

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Jan 13, 2026, 8:00 AM EST - 6 months ago

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Jan 12, 2026, 7:00 AM EST - 6 months ago

Alto Neuroscience Slides: Corporate presentation

Dec 3, 2025, 4:05 PM EST - 8 months ago

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Nov 28, 2025, 7:00 AM EST - 8 months ago

Alto Neuroscience Registration statement: Registration Filing

Nov 17, 2025, 10:30 AM EST - 8 months ago

Alto Neuroscience Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 10:00 AM EST - 8 months ago

Alto Neuroscience Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 8 months ago

Alto Neuroscience Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Alto Neuroscience Earnings release: Q3 2025

Nov 12, 2025, 7:57 AM EST - 8 months ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 7:34 AM EDT - 9 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 20, 2025, 7:03 AM EDT - 9 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:01 AM EDT - 9 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 8, 2025, 9:56 AM EDT - 10 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 10 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 7:34 AM EDT - 10 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Sep 17, 2025, 1:20 PM EDT - 10 months ago

Alto Neuroscience Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 2:00 PM EDT - 11 months ago

Alto Neuroscience Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:09 AM EDT - 11 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Aug 18, 2025, 9:45 AM EDT - 1 year ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 13, 2025, 4:10 PM EDT - 1 year ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alto Neuroscience Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Alto Neuroscience Earnings release: Q2 2025

Aug 13, 2025, 8:03 AM EDT - 1 year ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 4, 2025, 2:46 PM EDT - 1 year ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

TripleWitch Jul. 14 at 1:44 AM

$ANRO $PSNL You must mean the one that did the after hours equity offering, no? 🤷‍♂️

0 · Reply

RunnerSignals Jul. 13 at 7:53 PM

red to green $PSNL and $ANRO flipped the script into the close, but one reversal had the cleaner volume signature. traders may be watching the wrong winner

0 · Reply

focafoca99 Jul. 13 at 12:12 PM

$ANRO estimated its cash, cash equivalents and restricted cash at about $244.2 million as of June 30, 2026.

0 · Reply

MomentumSqueeze Jul. 13 at 11:44 AM

$ANRO news

0 · Reply

DiamondHandsJimbo Jul. 10 at 5:59 PM

$ANRO 😝🔥🚀

0 · Reply

DiamondHandsJimbo Jul. 10 at 4:43 PM

$ANRO show me some green LMAO… Entry at $26.14 🤞🚀

0 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:57 PM

$RILY $SLS $ANRO $OUST $POET The other half of that message from one year ago. What do you guys have planned for the next year? I guess, more importantly... What do WE have planned for next year?

3 · Reply

Ccperk Jun. 26 at 7:48 PM

$ANRO not exactly sure what’s going on here. Partnership or buyout imminent? Who knows

0 · Reply

focafoca99 Jun. 15 at 12:32 PM

$ANRO showed significant anhedonia reduction in a Nature Medicine study of pramipexole.

0 · Reply

dumb_money_wins_again Jun. 10 at 2:30 PM

$ANRO bring this back down to 3 dollars lol

0 · Reply

dumb_money_wins_again Jun. 10 at 1:31 PM

$ANRO

0 · Reply

dumb_money_wins_again Jun. 10 at 1:19 PM

$ANRO possible inverted head to poop emoji pattern! ALERT!!

0 · Reply

John1463 Jun. 10 at 11:26 AM

$ANRO: Alto Neuroscience stock is making a strong price recovery with increased bullish momentum and interest. It is climbing out of a stage of being oversold and has made a bullish crossover past the 20-day SMA, with extensive room to go up. It also has strong buy consensus with a price target at $35.13, meaning it still has the room for 66% upside.

0 · Reply

Ccperk Jun. 10 at 11:18 AM

$ANRO I’m not a huge technicals person but drawing the inverted cone method on the one year chart gives me a possible $50 by year end. With upcoming catalyst, new bd mem/bristol myer potential who knows. Will be an interesting Q3/4.

0 · Reply

dumb_money_wins_again Jun. 10 at 5:15 AM

$ANRO I think this tanks 50% lol. its a good time to short folks!

0 · Reply

InvestMRB Jun. 9 at 8:28 PM

$ANRO hmm this can push to 23.

0 · Reply

Stef_DL Jun. 9 at 3:36 PM

$ANRO The market is bleeding red and this does 7%+...

0 · Reply

focafoca99 May. 28 at 12:38 PM

$ANRO selected Andrew Miller, Ph.D., to its board of directors, adding biotech expertise.

1 · Reply

BossTrade May. 5 at 6:35 PM

$ANRO Timing another entry

1 · Reply

BossTrade May. 1 at 3:13 PM

$ANRO Hi Anro family. Hope everyone is doing well.

1 · Reply

BioTuesdays Apr. 27 at 4:23 PM

$ANRO has initiated its Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. https://biotuesdays.com/2026/04/27/alto-launches-phase-2b-trial-of-alto-207-in-trd/

0 · Reply

NYCDallas Apr. 22 at 6:48 PM

$ANRO just sold all shares up 43%

0 · Reply

Market Cap	966.49M
Revenue (ttm)	0.00
Net Income (ttm)	-63.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	617,900
Avg Vol	534,808
Day's Range	N/A - N/A
Shares Out	35.09M
Stochastic %K	31%
Beta	1.04
Analysts	Strong Sell
Price Target	$34.80